Cannabinoid influence on cytokine profile in multiple sclerosis

61Citations
Citations of this article
86Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cannabinoids have been suggested as possessing immunomodulatory properties, and cannabinoid receptors are present on leucocytes. Clinically, there is some evidence that cannabinoids may be therapeutically useful in treating multiple sclerosis, which is generally believed to be an autoimmune condition. This paper reports data derived from the Cannabinoids in MS (CAMS) study, which was the largest randomized controlled trial yet conducted to evaluate the therapeutic efficacy of cannabinoids. We found no evidence for cannabinoid influence on serum levels of interferon (IFN)-γ, interleukin (IL)-10, IL-12 or C-reactive protein as measured using enzyme-linked immunosorbent assay (ELISA), in comparison to control values. Mitogenic stimulation experiments also failed to demonstrate any significant reduction in percentage of CD3+, IFN-γ producing cells after exposure to cannabinoids in vivo, although numbers were small. Further work is needed to establish the functional significance of cannabinoid receptors on immune cells. © 2005 British Society for Immunology.

Cite

CITATION STYLE

APA

Katona, S., Kaminski, E., Sanders, H., & Zajicek, J. (2005). Cannabinoid influence on cytokine profile in multiple sclerosis. Clinical and Experimental Immunology, 140(3), 580–585. https://doi.org/10.1111/j.1365-2249.2005.02803.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free